甲状腺髓样癌靶向治疗的研究进展

甲状腺髓样癌（MTC）是起源于甲状腺C细胞的恶性肿瘤，因其细胞功能的特殊性，治疗主要以及时甲状腺根治性外科手术为首选。但多数患者即使早期也易发生转移，且细胞又缺乏钠碘共同转运体的表达，不能进行放射性碘治疗。近年来，酪氨酸激酶抑制剂靶向治疗的临床应用不断扩大，同时放射性核素靶向治疗及其他靶向治疗正进入一个快速发展的时期，为MTC的治疗带来了契机。笔者重点阐述近年来MTC靶向治疗方面的研究进展。

Research status of medullary thyroid carcinoma targeted therapy

Medullary thyroid carcinoma (MTC) is a malignant tumor that originated from the C cells of thyroid. Given its special function, timely radical thyroid operation is the preferred treatment for this tumor. However, most patients are prone to early metastasis, and the sodium/iodide symporter is unexpressed on the C cell surface. Therefore, this tumor cannot be treated with radioactive iodine. In recent years, the clinical application of targeted therapy with tyrosine kinase inhibitors is increasing. Furthermore, radionuclide therapy and other interventional targeted therapies are becoming rapidly developed, which results in an opportunity to manage the aggressive medullary thyroid cancer.